 Page 01
Investment Portfolio
• Investment portfolio substantially cash
independent of ANGLE.
• Corporate deal for Novocellus (IVF embryo
viability) with Origio (formerly MediCult).
• Parsortix world break-through by isolating
foetal cells in maternal blood.
Contents
Highlights 01
Management services 02
Investment Portfolio 03
A helping hand 04
True-to-life 06
Chairman’s Statement 08
Chief Executive’s Statement 10
Financial Review 14
Board of Directors 16
Directors’ Report 18
Corporate Governance Report 20
Remuneration Report 23
Independent Auditor’s Report 25
Consolidated Income Statement 26
Consolidated Balance Sheet 27
Consolidated Cash Flow
Statement 28
Consolidated Statement of Changes
in Equity 29
Notes to the Consolidated Financial
Statements 30
Company Balance Sheet 51
Notes to the Company Financial
Statements 52
Notice of Annual General Meeting 55
Form of Proxy 59
Directors and Advisors 61
Operational Highlights
Group
• Group cash generative prior to
discretionary expenditure on investment
portfolio.
Management services
• Revenues increased by 28% to £4.9 million
(2008: £3.8 million).
• Profit before tax from Management
services increased by 41% to £1.6 million
(2008: £1.1 million).
• Successful completion in March 2009 of
five year contract to develop the highly
successful Qatar Science & Technology
Park.
• Continued progress in winning significant
cash generative management contracts.
• Significant business development in the
Middle East with strong growth prospects
developing.
